GlassScriptPhysician profile
Lori Nolan
NPI 1033677646
$851.99
in general payments reported to CMS, 2019-2025
13 companies · $58.98 in 2025
The $58.98 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.96 · 2022: $12.92 · 2023: $528 · 2024: $226 · 2025: $58.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $812.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $812.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $121.96 | 2023-2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $114.40 | 2023-2024 | Austedo Xr, Austedo |
| Uswm, LLC | $102.72 | 2023 | Lucemyra, Zimhi |
| Abbvie INC. | $97.25 | 2023-2025 | |
| Axsome Therapeutics, INC. | $81.59 | 2023 | Auvelity |
| Alkermes, INC. | $76.75 | 2023-2025 | Aristada, Vivitrol, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $73.01 | 2023 | Rexulti |
| Almatica Pharma LLC | $58.53 | 2023 | Loreev Xr |
| Neurocrine Biosciences, INC. | $52.64 | 2023-2024 | Ingrezza |
| Genentech USA, INC. | $26.96 | 2021 | |
| Braeburn INC. | $17.81 | 2024 | Brixadi |
| Idorsia Pharmaceuticals US INC | $15.45 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Nolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.